Inventor · disambiguated record
Yanan Guo
Also filed as: GUO YANAN
42 granted patents·28 pending applications·30 citations·filing 2014–2024
96Inventor score
Files withBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD43EUCURE BEIJING BIOPHARMA CO LTD15BEIJING BIOCYTOGEN CO LTD3UNIV BEIJING TECHNOLOGY3BIOCYTOGEN JIANGSU CO LTD2
Top patents by PatentIndex Score
70 records- 0191US10918095B2Genetically modified mice expressing humanized CD47BEIJING BIOCYTOGEN CO LTD·Filed 2019·Granted Feb 16, 2021·5 cites·15 claims
- 0290US10820580B2Immunodeficient non-human animalBEIJING BIOCYTOGEN CO LTD·Filed 2019·Granted Nov 3, 2020·5 cites·7 claims
- 0389US10934365B2Anti-OX40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Granted Mar 2, 2021·2 cites·25 claims
- 0489US10570024B2Method for effluent total nitrogen-based on a recurrent self-organizing RBF neural networkUNIV BEIJING TECHNOLOGY·Filed 2016·Granted Feb 25, 2020·5 cites·1 claims
- 0588US11352429B2Anti-PD-1 antibodies and uses thereofBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2021·Granted Jun 7, 2022·1 cites·26 claims
- 0688US10973212B2Genetically modified non-human animal with human or chimeric SIRPaBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Apr 13, 2021·4 cites·19 claims
- 0785US11142582B2Anti-CD40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Oct 12, 2021·1 cites·14 claims
- 0884US12323092B2Tracking type flexible photovoltaic bracketUNIV XIAN ARCHITECTUR & TECH·Filed 2023·Granted Jun 3, 2025·1 cites·7 claims
- 0983US11439132B2Humanized transgenic animalBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2020·Granted Sep 13, 2022·1 cites·14 claims
- 1082US11034764B2Anti-CTLA4 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Granted Jun 15, 2021·1 cites·18 claims
- 1182US10945420B2Genetically modified non-human animal with human or chimeric CD3eBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Mar 16, 2021·1 cites·18 claims
- 1282US10912287B2Genetically modified mice expressing humanized PD-1BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2017·Granted Feb 9, 2021·2 cites·13 claims
- 1381US2025129164A1Anti-pd-1 antibodies and uses thereofBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2024·Application pending·0 cites
- 1480US10925264B2Genetically modified non-human animal with human or chimeric LAG-3BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Feb 23, 2021·1 cites·12 claims
- 1580US2025034271A1Anti-cd40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 1680US2025034256A1Anti-pd-1 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 1779US2024343806A1Anti-ctla4 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 1878US2024352141A1Anti-ox40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 1977US2024092922A1Anti-tnfrsf9 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2023·Application pending·0 cites
- 2075US12180281B2Anti-PD-1 antibodies and methods of treating cancerBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2022·Granted Dec 31, 2024·0 cites·30 claims
- 2172US12134653B2Anti-CD40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Nov 5, 2024·0 cites·16 claims
- 2272US11723348B2Genetically modified mice expressing humanized CD47BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2020·Granted Aug 15, 2023·0 cites·13 claims
- 2370US11071290B2Genetically modified non-human animal with human or chimeric CTLA-4BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Jul 27, 2021·0 cites·13 claims
- 2470US2022251229A1Anti-tnfrsf9 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2022·Application pending·0 cites
- 2569US11292849B2Anti-TNFRSF9 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Apr 5, 2022·0 cites·33 claims
- 2669US2023043907A1Humanized transgenic animalBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2022·Application pending·0 cites
- 2768US12342800B2Immunodeficient non-human animalBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2020·Granted Jul 1, 2025·0 cites·21 claims
- 2867US12054547B2Anti-CTLA4 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Aug 6, 2024·0 cites·18 claims
- 2967US11999790B2Anti-OX40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Jun 4, 2024·0 cites·17 claims
- 3067US11154041B2Genetically modified non-human animal with human or chimeric genesBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2020·Granted Oct 26, 2021·0 cites·17 claims
- 3167US2021403570A1Anti-pd-1 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Application pending·0 cites
- 3266US12016315B2Genetically modified non-human animal with human or chimeric CD3eBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2021·Granted Jun 25, 2024·0 cites·19 claims
- 3365US11155625B2Anti-PD-1 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Granted Oct 26, 2021·0 cites·43 claims
- 3465US10980222B2Genetically modified non-human animal with human or chimeric CD27BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Apr 20, 2021·0 cites·12 claims
- 3564US11464876B2Genetically modified mouse comprising a chimeric TIGITBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Oct 11, 2022·0 cites·5 claims
- 3664US11234420B2Method for constructing PD-1 gene modified humanized animal model and use thereofBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Feb 1, 2022·0 cites·15 claims
- 3764US2022000086A1Genetically modified non-human animal with human or chimeric genesBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2021·Application pending·0 cites
- 3863US11240995B2Genetically modified non-human animal with human or chimeric TIM-3BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Feb 8, 2022·0 cites·20 claims
- 3962US11096383B2Method of using a genetically modified mouse that expresses a humanized CTLA-4 geneBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2017·Granted Aug 24, 2021·0 cites·13 claims
- 4061US10945419B2Genetically modified non-human animal with human or chimeric GITRBEIJING BIOCYTOGEN CO LTD·Filed 2019·Granted Mar 16, 2021·0 cites·23 claims
- 4160US11272695B2Genetically modified non-human animal with human or chimeric PD-1BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Mar 15, 2022·0 cites·15 claims
- 4260US10945418B2Genetically modified non-human animal with human or chimeric PD-L1BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Mar 16, 2021·0 cites·11 claims
- 4358US11497198B2Genetically modified mice expressing humanized CD40BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Nov 15, 2022·0 cites·4 claims
- 4455US11534502B2Genetically modified non-human animal with human or chimeric TIGITBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2017·Granted Dec 27, 2022·0 cites·6 claims
- 4555US11317611B2Genetically modified non-human animal with human or chimeric PD-L1BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2017·Granted May 3, 2022·0 cites·13 claims
- 4655US2023227531A1Genetically modified non-human animal expressing a b2m/fcrn fusion proteinBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2021·Application pending·0 cites
- 4755US2022071185A1Genetically modified non-human animal with human or chimeric cd137BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2021·Application pending·0 cites
- 4854US2023363362A1Genetically modified non-human animal with human or chimeric glp1rBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2021·Application pending·0 cites
- 4954US2023165227A1Genetically modified non-human animal with human or chimeric cd276BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2021·Application pending·0 cites
- 5054US2023148574A1Genetically modified non-human animal with human or chimeric cd38BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2021·Application pending·0 cites
Showing the top 50 of 70 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →